5/1/2013

Incyte earned a $25 million milestone fee from Novartis for initiating a midstage trial of their experimental drug INC280 for the treatment of advanced hepatocellular carcinoma. The drug is a c-MET receptor tyrosine kinase inhibitor.

Related Summaries